Injectable medicine is heading for its biggest shake-up in decades. Vials and ampoules have served the industry well, and they’ll stay in use. But biologics, GLP-1 therapies and biosimilars, along with a push to fit treatment around patients' lives, are exposing what those formats struggle to offer: easy self-injection, accurate doses and less work for health systems.

Treatment is leaving the clinic

Not long ago, a patient on a biologic would visit an infusion center and be treated by trained staff. 

Now drugmakers are designing therapies for use at home from day one. Chronic disease is more common, biologics and biosimilars keep multiplying, populations are ageing, healthcare costs are climbing, and patients expect a better experience, often with digital tools alongside.

Prefilled syringes and autoinjectors fit that shift. They make an injection simpler, need less training, cut dosing errors and make it easier for people to stay on treatment. 

For manufacturers, the device is no longer something to settle late in development. It is part of the launch plan from the beginning.

A format for every therapy

Each platform has found its niche:

• Prefilled syringes suit vaccines, monoclonal antibodies, emergency medicines and specialty injectables.
• Cartridges are the usual choice for pen injectors, reusable devices and large chronic disease markets.
• Autoinjectors are growing quickly in autoimmune disorders, severe allergies, diabetes, obesity and multiple sclerosis.

GLP-1 therapies alone are expected to drive a surge in demand for all of them.

The factory has to change too

Fill-finish used to mean getting a drug safely into its container. The next generation of plants will be judged on how well they deliver it. 

That calls for skills many sites don't have yet, such as device assembly, human factors engineering and functional testing of the finished product, and it points to production lines that handle prefilled syringes, automated assembly and connected data.

Materials are shifting as well. Cyclo olefin polymers and copolymers (COC and COP) are gaining ground as an alternative to glass. They break less, shed fewer particles, avoid tungsten contamination concerns and hold their dimensions more consistently, which suits delicate biologics.

Automation is the other big lever. Robotics, vision inspection, AI-assisted quality checks and digital batch records are already appearing in new facilities. 

The goal is a fully connected plant where packaging, device assembly, serialization and release testing share one digital system.

Smarter devices, lighter footprint

Tomorrow's autoinjectors may track doses, monitor adherence, connect wirelessly and share treatment data with clinicians. A company's offer then becomes the medicine, the device, the data and the support around the patient, all as one.

Sustainability will matter too. Health systems and regulators are weighing carbon footprint, packaging waste, transport efficiency and recyclability when they buy.

Who benefits

Jaywant Pawar, a pharma packaging specialist, argues that the winners will be organizations that can bring together drug development, device engineering, packaging, advanced manufacturing and digital health. In his words, they will deliver complete therapeutic experiences, not just manufacture drugs.

Avicenna is developing a sealed, plungerless cartridge platform with a reusable injector, aimed at extending drug stability and shelf life.